277 related articles for article (PubMed ID: 19857798)
1. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
Müller L; Gocke E
Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
[TBL] [Abstract][Full Text] [Related]
2. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
3. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
4. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
[TBL] [Abstract][Full Text] [Related]
5. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
Gocke E; Bürgin H; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
[TBL] [Abstract][Full Text] [Related]
6. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
7. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
8. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
9. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
Gocke E; Wall M
Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
[TBL] [Abstract][Full Text] [Related]
10. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
Gocke E; Ballantyne M; Whitwell J; Müller L
Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
[TBL] [Abstract][Full Text] [Related]
11. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
Gocke E; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
[TBL] [Abstract][Full Text] [Related]
12. Setting health-based residue limits for contaminants in pharmaceuticals and medical devices.
Conine DL; Naumann BD; Hecker LH
Qual Assur; 1992 Jun; 1(3):171-80. PubMed ID: 1344672
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
Gocke E; Müller L
Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Eichenbaum G; Johnson M; Kirkland D; O'Neill P; Stellar S; Bielawne J; DeWire R; Areia D; Bryant S; Weiner S; Desai-Krieger D; Guzzie-Peck P; Evans DC; Tonelli A
Regul Toxicol Pharmacol; 2009 Oct; 55(1):33-42. PubMed ID: 19500632
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
[TBL] [Abstract][Full Text] [Related]
17. General 4-week toxicity study with EMS in the rat.
Pfister T; Eichinger-Chapelon A
Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
[TBL] [Abstract][Full Text] [Related]
18. Non-linear dose-response of DNA-reactive genotoxins: recommendations for data analysis.
Johnson GE; Doak SH; Griffiths SM; Quick EL; Skibinski DO; Zaïr ZM; Jenkins GJ
Mutat Res; 2009 Aug; 678(2):95-100. PubMed ID: 19467345
[TBL] [Abstract][Full Text] [Related]
19. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
20. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]